Headlines about Fortress Biotech (NASDAQ:FBIO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a news impact score of 0.00 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.3550140808421 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern’s scoring:

Shares of Fortress Biotech (FBIO) traded up $0.09 during trading hours on Friday, hitting $4.24. 224,832 shares of the company were exchanged, compared to its average volume of 145,742. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.42. The stock has a market cap of $214.78, a P/E ratio of -2.33 and a beta of 0.45. Fortress Biotech has a 52 week low of $3.13 and a 52 week high of $5.13.

FBIO has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Fortress Biotech from a “hold” rating to a “sell” rating in a report on Friday, December 1st. HC Wainwright set a $11.00 price target on shares of Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Zacks Investment Research downgraded shares of Fortress Biotech from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Finally, B. Riley initiated coverage on shares of Fortress Biotech in a report on Wednesday. They issued a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.80.

In related news, SVP George Avgerinos sold 25,593 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $3.59, for a total value of $91,878.87. Following the transaction, the senior vice president now directly owns 409,088 shares of the company’s stock, valued at approximately $1,468,625.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 33.30% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/fortress-biotech-fbio-given-daily-news-impact-rating-of-0-00/1907355.html.

About Fortress Biotech

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.